![Albert Tsai](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Albert Tsai is Chief Medical Officer at VivaVision Biotech (Zhejiang) Co., Ltd. since 2025.
Formerly, Dr. Tsai was Vice President at PPD, Inc. from 2019 to 2021 and Chief Medical Officer at Zhaoke Ophthalmology Ltd. Education includes an MBA from the University of Southern California and a doctorate from Northwestern University.
Postes actifs de Albert Tsai
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Albert Tsai
| Sociétés | Poste | Fin |
|---|---|---|
| PPD, INC. | Corporate Officer/Principal | 01/01/2021 |
| ZHAOKE OPHTHALMOLOGY LIMITED | Directeur Technique/Scientifique/R&D | - |
Formation de Albert Tsai
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
14
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PPD, Inc.
 PPD, Inc. BiotechnologyHealth Technology Engages in research and development of biopharmaceutical industry | Health Technology |
Zhaoke Ophthalmology Ltd.
 Zhaoke Ophthalmology Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and supplies ophthalmic topical drugs | Health Technology |
